Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingo Jordan

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Viruses|April 16, 2014
Matrix and backstage: cellular substrates for viral vaccinesIngo Jordan, Volker Sandig
BMC Proceedings|March 1, 2012
Highly efficient, chemically defined and fully scalable biphasic production of vaccine virusesIngo Jordan, Volker Sandig
Viruses|July 4, 2012
Authentication of the R06E fruit bat cell lineIngo Jordan, Vincent J Munster, Volker Sandig
Cellular and Molecular Life Sciences : CMLS|October 19, 2018
mRNA as novel technology for passive immunotherapyThomas Schlake, Andreas Thess, Moritz Thran, et al.
Plos One|August 25, 2017
Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systemsFelipe Tapia, Ingo Jordan, Yvonne Genzel, et al.
Viruses|January 23, 2013
A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined mediumIngo Jordan, Deborah Horn, Katrin John, et al.
Microorganisms|October 4, 2016
Elements in the Development of a Production Process for Modified Vaccinia Virus AnkaraIngo Jordan, Verena Lohr, Yvonne Genzel, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2012
Fucose-targeted glycoengineering of pharmaceutical cell linesChristiane Ogorek, Ingo Jordan, Volker Sandig, et al.
Virus Research|June 23, 2009
Cell lines from the Egyptian fruit bat are permissive for modified vaccinia AnkaraIngo Jordan, Deborah Horn, Stefanie Oehmke, et al.
Vaccine|February 14, 2018
High-cell-density cultivations to increase MVA virus productionDaniel Vázquez-Ramírez, Yvonne Genzel, Ingo Jordan, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Viruses|April 16, 2014
Matrix and backstage: cellular substrates for viral vaccinesIngo Jordan, Volker Sandig
BMC Proceedings|March 1, 2012
Highly efficient, chemically defined and fully scalable biphasic production of vaccine virusesIngo Jordan, Volker Sandig
Viruses|July 4, 2012
Authentication of the R06E fruit bat cell lineIngo Jordan, Vincent J Munster, Volker Sandig
Cellular and Molecular Life Sciences : CMLS|October 19, 2018
mRNA as novel technology for passive immunotherapyThomas Schlake, Andreas Thess, Moritz Thran, et al.
Plos One|August 25, 2017
Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systemsFelipe Tapia, Ingo Jordan, Yvonne Genzel, et al.
Viruses|January 23, 2013
A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined mediumIngo Jordan, Deborah Horn, Katrin John, et al.
Microorganisms|October 4, 2016
Elements in the Development of a Production Process for Modified Vaccinia Virus AnkaraIngo Jordan, Verena Lohr, Yvonne Genzel, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2012
Fucose-targeted glycoengineering of pharmaceutical cell linesChristiane Ogorek, Ingo Jordan, Volker Sandig, et al.
Virus Research|June 23, 2009
Cell lines from the Egyptian fruit bat are permissive for modified vaccinia AnkaraIngo Jordan, Deborah Horn, Stefanie Oehmke, et al.
Vaccine|February 14, 2018
High-cell-density cultivations to increase MVA virus productionDaniel Vázquez-Ramírez, Yvonne Genzel, Ingo Jordan, et al.
Pageof 5